Abbreviated name: TUDA
Synonyms: tauroursodeoxycholate | taurursodiol | TUDCA | UR 906 | ursodoxicoltaurine (INN)
Compound class:
Metabolite or derivative
Comment: Tauroursodeoxycholic acid (TUDCA) is a conjugated bile acid derivative. Evidence suggests that it acts as a chemical chaperone and facilitates protein folding within the endoplasmic reticulum [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
An orally bioavailable fixed-dose coformulation containing tauroursodeoxycholic acid (taurursodiol) and sodium phenylbutyrate, known as AMX0035 (PB-TURSO; Amylyx Pharmaceuticals) is being investigated for clinical efficacy in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) [3-4]. Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal death in experimental models, which suggests potential to treat human neurodegeneration [6]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03127514 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Phase 2/Phase 3 Interventional | Amylyx Pharmaceuticals Inc. | 3-4 |